You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
智飛生物(300122.SZ)擬向智飛龍科馬增資5億元 促進公司疫苗產品發展與產業化
格隆匯 10-21 20:36

格隆匯10月21日丨智飛生物(300122.SZ)公佈,為了進一步促進公司疫苗產品的發展與產業化,結合全資子公司安徽智飛龍科馬生物製藥有限公司(“智飛龍科馬”或“子公司”)的戰略規劃需要,公司擬以自籌資金人民幣5億元對智飛龍科馬進行增資。此次增資完成後,智飛龍科馬的註冊資本將由2.65億元增加至7.65億元,仍為公司全資子公司。

安徽智飛龍科馬生物製藥有限公司許可經營項目:生物製品(免疫製劑,疫苗,基因重組製品)生產、銷售。一般經營項目:生物製品、藥品、診斷試劑及醫療器械的技術開發、技術轉讓、技術服務;生物技術諮詢服務;實驗用免疫試劑、實驗儀器銷售;低温倉儲;冷藏車道路運輸;實驗動物養殖;進出口業務。

公司此次對全資子公司智飛龍科馬增資主要為了進一步增強智飛龍科馬的資本實力,滿足其發展需要,有利於更好地實現公司的經營發展戰略,此次增資不會對公司財務狀況和經營成果在本年度產生重大影響,不存在損害上市公司股東利益的情形。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account